https://fgmed.org/blog/cardio-ttransform-eplontersen-nao-atinge-desfecho-primario-na-attr-cm/
CARDIO-TTRansform: Eplontersen não atinge desfecho primário na ATTR-CM - FGMED
Jul 9, 2026 - CARDIO-TTRansform: o que o resultado do eplontersen revela sobre o futuro da ATTR-CM Estudo CARDIO-TTRansform avaliou eplontersen na cardiomiopatia amiloide...
cardioeplontersenatingedesfechoattr
https://www.astrazeneca-us.com/media/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-through-66-weeks.html
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated...
phase iii trialeplontersendemonstratedsustainedbenefit